[Disclosure] Celltrion (068270) Secures Final FDA Approval for ‘Omlyclo’, a Biosimilar of Xolair

Source: Financial Supervisory Service Dart System / 2025-03-10

Disclosure Type: Key Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion’s ‘Omlyclo’, a biosimilar of the multiple disease treatment Xolair, has obtained final marketing authorization from the U.S. Food and Drug Administration (FDA) for all of the reference product’s indications, including asthma and chronic spontaneous urticaria.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Product Name: Omlyclo (Development name: CT-P39, Reference product: Xolair, Active ingredient: Omalizumab)
• Target Indications:
  • Asthma
  • Chronic Rhinosinusitis with Nasal Polyps
  • Chronic Spontaneous Urticaria
  • IgE-Mediated Food Allergy
• Timeline of Application & Approval:
  • Application Date: March 8, 2024 (Local Time)
  • Approval Date: March 7, 2025 (Local Time)
• Approval Authority: U.S. Food and Drug Administration (FDA)
• Operational Plan & Expected Effect: Celltrion plans to sell Omlyclo (CT-P39) across the United States through its US subsidiary. Obtaining final approval for all indications authorized for the reference product is expected to provide treatment options to a broader patient base.

📈 2. [Expert Perspective: What This Means for Investors]

• Official Marketing Rights in the US: This disclosure confirms that Omlyclo (CT-P39) has received final marketing authorization from the U.S. Food and Drug Administration (FDA) following a review process of approximately one year. This establishes the regulatory framework required to legally distribute the product in the US market.
• Comprehensive Indication Alignment: The approval covers all indications authorized for the reference biologic, ‘Xolair’, including asthma, chronic spontaneous urticaria, and IgE-mediated food allergy. This ensures that the biosimilar is regulatory aligned with the exact therapeutic scope of the original drug.
• Local Distribution Operations: As specified in the filing, actual product sales will be executed via Celltrion’s established US subsidiary, which is planned to handle the distribution and marketing of CT-P39 across the United States.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has obtained final marketing authorization from the U.S. FDA for its Xolair biosimilar, ‘Omlyclo (CT-P39)’. Receiving the official approval document approximately one year after the initial filing in March 2024 marks the completion of the formal regulatory review process required to initiate the commercial process in the United States.

The primary check point for investors moving forward is the actual commercial launch date and the follow-up progress of distribution through Celltrion’s US subsidiary. Investors should track future corporate filings to identify the timeline for when physical product shipments across the United States officially commence under the approved plan.

Rather than making assumptions about future sales performance, investors are advised to objectively follow subsequent verified disclosures and periodic financial statements to monitor the progress of the company’s stated US sales plan.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.